Appropriate Minimal Dose of Gadobutrol for 3D Time-Resolved MRA of the Supra-Aortic Arteries: Comparison with Conventional Single-Phase High-Resolution 3D Contrast-Enhanced MRA

References

1. 1.↵
   2. Krings T,
   3. Hans F

   . New developments in MRA: time-resolved MRA. Neuroradiology 2004;46(suppl 2):s214–22 doi:10.1007/s00234-004-1332-x pmid:15645155

   CrossRefPubMed
2. 2.↵
   2. Lee YJ,
   3. Laub G,
   4. Jung SL, et al

   . Low-dose 3D time-resolved magnetic resonance angiography (MRA) of the supraaortic arteries: correlation with high spatial resolution 3D contrast-enhanced MRA. J Magn Reson Imaging 2011;33:71–76 doi:10.1002/jmri.22396 pmid:21182123

   CrossRefPubMed
3. 3.↵
   2. Lim RP,
   3. Shapiro M,
   4. Wang EY, et al

   . 3D time-resolved MR angiography (MRA) of the carotid arteries with time-resolved imaging with stochastic trajectories: comparison with 3D contrast-enhanced bolus-chase MRA and 3D time-of-flight MRA. AJNR Am J Neuroradiol 2008;29:1847–54 doi:10.3174/ajnr.A1252 pmid:18768727

   Abstract/FREE Full Text
4. 4.↵
   2. Thiex R,
   3. Norbash AM,
   4. Frerichs KU

   . The safety of dedicated-team catheter-based diagnostic cerebral angiography in the era of advanced noninvasive imaging. AJNR Am J Neuroradiol 2010;31:230–34 doi:10.3174/ajnr.A1803 pmid:19779004

   CrossRefPubMed
5. 5.↵
   2. Tomasian A,
   3. Salamon N,
   4. Lohan DG, et al

   . Supraaortic arteries: contrast material dose reduction at 3.0-T high-spatial-resolution MR angiography—feasibility study. Radiology 2008;249:980–90 doi:10.1148/radiol.2493080209 pmid:19011192

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Thomsen HS,
   3. Morcos SK,
   4. Almén T, et al

   ; ESUR Contrast Medium Safety Committee. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2013;23:307–18 doi:10.1007/s00330-012-2597-99 pmid:22865271

   CrossRefPubMed
7. 7.↵
   2. Zhang B,
   3. Liang L,
   4. Chen W, et al

   . An updated study to determine association between gadolinium-based contrast agents and nephrogenic systemic fibrosis. PLoS One 2015;10:e0129720 doi:10.1371/journal.pone.0129720 pmid:26076348

   CrossRefPubMed
8. 8.↵
   2. Broome DR,
   3. Girguis MS,
   4. Baron PW, et al

   . Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188:586–92 doi:10.2214/AJR.06.1094 pmid:17242272

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Collidge TA,
   3. Thomson PC,
   4. Mark PB, et al

   . Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168–75 doi:10.1148/radiol.2451070353 pmid:17704357

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Kallen AJ,
    3. Jhung MA,
    4. Cheng S, et al

    . Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51:966–75 doi:10.1053/j.ajkd.2007.12.036 pmid:18501784

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Marckmann P,
    3. Skov L,
    4. Rossen K, et al

    . Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174–78 doi:10.1093/ndt/gfm261 pmid:17483196

    Abstract/FREE Full Text
12. 12.↵
    2. McDonald RJ,
    3. McDonald JS,
    4. Kallmes DF, et al

    . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194

    CrossRefPubMed
13. 13.↵
    2. Ramalho J,
    3. Semelka RC,
    4. Ramalho M, et al

    . Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol 2016;37:1192–98 doi:10.3174/ajnr.A4615 pmid:26659341

    Abstract/FREE Full Text
14. 14.↵
    2. Stojanov DA,
    3. Aracki-Trenkic A,
    4. Vojinovic S, et al

    . Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 2016;26:807–15 doi:10.1007/s00330-015-3879-9 pmid:26105022

    CrossRefPubMed
15. 15.↵
    2. Karabulut N

    . Gadolinium deposition in the brain: another concern regarding gadolinium-based contrast agents. Diagn Interv Radiol 2015;21:269–70 doi:10.5152/dir.2015.001 pmid:26133320

    CrossRefPubMed
16. 16.↵
    2. Nael K,
    3. Moriarty JM,
    4. Finn JP

    . Low dose CE-MRA. Eur J Radiol 2011;80:2–8 doi:10.1016/j.ejrad.2011.01.092 pmid:21458187

    CrossRefPubMed
17. 17.↵
    2. Nael K,
    3. Michaely HJ,
    4. Villablanca P, et al

    . Time-resolved contrast enhanced magnetic resonance angiography of the head and neck at 3.0 tesla: initial results. Invest Radiol 2006;41:116–24 doi:10.1097/01.rli.0000192416.19801.ca pmid:16428982

    CrossRefPubMed
18. 18.↵
    2. Kramer U,
    3. Fenchel M,
    4. Laub G, et al

    . Low-dose, time-resolved, contrast-enhanced 3D MR angiography in the assessment of the abdominal aorta and its major branches at 3 Tesla. Acad Radiol 2010;17:564–76 doi:10.1016/j.acra.2009.12.011 pmid:20171907

    CrossRefPubMed
19. 19.↵
    2. Krishnam MS,
    3. Tomasian A,
    4. Lohan DG, et al

    . Low-dose, time-resolved, contrast-enhanced 3D MR angiography in cardiac and vascular diseases: correlation to high spatial resolution 3D contrast-enhanced MRA. Clin Radiol 2008;63:744–55 doi:10.1016/j.crad.2008.01.001 pmid:18555032

    CrossRefPubMed
20. 20.↵
    2. Lohan DG,
    3. Tomasian A,
    4. Saleh RS, et al

    . Ultra-low-dose, time-resolved contrast-enhanced magnetic resonance angiography of the carotid arteries at 3.0 Tesla. Invest Radiol 2009;44:207–17 doi:10.1097/RLI.0b013e31819ca048 pmid:19300100

    CrossRefPubMed
21. 21.↵
    2. Ferguson GG,
    3. Eliasziw M,
    4. Barr HW, et al

    . The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. Stroke 1999;30:1751–58 doi:10.1161/01.STR.30.9.1751 pmid:10471419

    Abstract/FREE Full Text
22. 22.↵
    2. Bonvento MJ,
    3. Moore WH,
    4. Button TM, et al

    . CT angiography with gadolinium-based contrast media. Acad Radiol 2006;13:979–85 doi:10.1016/j.acra.2006.03.019 pmid:16843850

    CrossRefPubMed
23. 23.↵
    2. Stojanov D,
    3. Aracki-Trenkic A,
    4. Benedeto-Stojanov D

    . Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status. Neuroradiology 2016;58:433–41 doi:10.1007/s00234-016-1658-1 pmid:26873830

    CrossRefPubMed
24. 24.↵
    2. Remonda L,
    3. Senn P,
    4. Barth A, et al

    . Contrast-enhanced 3D MR angiography of the carotid artery: comparison with conventional digital subtraction angiography. AJNR Am J Neuroradiol 2002;23:213–19 pmid:11847044

    Abstract/FREE Full Text
25. 25.↵
    2. Lee YJ,
    3. Kim BS,
    4. Koo JS, et al

    . Supra-aortic low-dose contrast-enhanced time-resolved magnetic resonance (MR) angiography at 3 T: comparison with time-of-flight MR angiography and high-resolution contrast-enhanced MR angiography. Acta Radiol 2015;56:673–80 doi:10.1177/0284185114538426 pmid:24951617

    CrossRefPubMed
26. 26.↵
    2. Haneder S,
    3. Kucharczyk W,
    4. Schoenberg SO, et al

    . Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis. Top Magn Reson Imaging 2015;24:57–65 doi:10.1097/RMR.0b013e3182a14e79 pmid:25654421

    CrossRefPubMed
27. 27.↵
    2. Carroll TJ,
    3. Korosec FR,
    4. Petermann GM, et al

    . Carotid bifurcation: evaluation of time-resolved three-dimensional contrast-enhanced MR angiography. Radiology 2001;220:525–32 doi:10.1148/radiology.220.2.r01au43525 pmid:11477264

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Du J,
    3. Fain SB,
    4. Korosec FR, et al

    . Time-resolved contrast-enhanced carotid imaging using undersampled projection reconstruction acquisition. J Magn Reson Imaging 2007;25:1093–99 doi:10.1002/jmri.20890 pmid:17410565

    CrossRefPubMed
29. 29.↵
    2. Watts R,
    3. Wang Y,
    4. Redd B, et al

    . Recessed elliptical-centric view-ordering for contrast-enhanced 3D MR angiography of the carotid arteries. Magn Reson Med 2002;48:419–24 doi:10.1002/mrm.10235 pmid:12210905

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Raoult H,
    3. Ferré JC,
    4. Morandi X, et al

    . Quality-evaluation scheme for cerebral time-resolved 3D contrast-enhanced MR angiography techniques. AJNR Am J Neuroradiol 2010;31:1480–87 doi:10.3174/ajnr.A2093 pmid:20448014

    Abstract/FREE Full Text
31. 31.↵
    2. Riederer SJ,
    3. Haider CR,
    4. Borisch EA, et al

    . Recent advances in 3D time-resolved contrast-enhanced MR angiography. J Magn Reson Imaging 2015;42:3–22 doi:10.1002/jmri.24880 pmid:26032598

    CrossRefPubMed
32. 32.↵
    2. Choi JW,
    3. Roh HG,
    4. Moon WJ, et al

    . Time-resolved 3D contrast-enhanced MRA on 3.0T: a non-invasive follow-up technique after stent-assisted coil embolization of the intracranial aneurysm. Korean J Radiol 2011;12:662–70 doi:10.3348/kjr.2011.12.6.662 pmid:22043147

    CrossRefPubMed
33. 33.↵
    2. Voth M,
    3. Michaely HJ,
    4. Schwenke C, et al

    . Contrast-enhanced magnetic resonance angiography (MRA): evaluation of three different contrast agents at two different doses (0.05 and 0.1 mmol/kg) in pigs at 1.5 Tesla. Eur Radiol 2011;21:337–44 doi:10.1007/s00330-010-1940-2 pmid:20809127

    CrossRefPubMed
34. 34.↵
    2. Kim S,
    3. Lee S,
    4. Choi HS, et al

    . Pseudostenosis at the origin of the vertebral artery on contrast-enhanced MRA: correlation with aortic motion on dynamic 3D time-resolved contrast-enhanced MRA. J Korean Society of Magnetic Resonance in Medicine 2012;16:236–42
35. 35.↵
    2. Nael K,
    3. Krishnam M,
    4. Ruehm SG, et al

    . Time-resolved MR angiography in the evaluation of central thoracic venous occlusive disease. AJR Am J Roentgenol 2009;192:1731–38 doi:10.2214/AJR.08.1919 pmid:19457842

    CrossRefPubMed